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Abstract
Background: Tumor DNA has been shown to be present both in circulating tumor cells in blood and as fragments in the
plasma of metastatic cancer patients. The identification of ultra-rare tumor-specific mutations in blood would be the
ultimate marker to measure efficacy of cancer therapy and/ or early recurrence. Herein we present a method for detecting
microinsertions/deletions/indels (MIDIs) at ultra-high analytical selectivity. MIDIs comprise about 15% of mutations.
Methods and Findings: We describe MIDI-Activated Pyrophosphorolysis (MAP), a method of ultra-high analytical selectivity
for detecting MIDIs. The high analytical selectivity of MAP is putatively due to serial coupling of two rare events:
heteroduplex slippage and mis-pyrophosphorolysis. MAP generally has an analytical selectivity of one mutant molecule per
.1 billion wild type molecules and an analytical sensitivity of one mutant molecule per reaction. The analytical selectivity of
MAP is about 100,000-fold better than that of our previously described method of Pyrophosphorolysis Activated
Polymerization-Allele specific amplification (PAP-A) for detecting MIDIs. The utility of this method is illustrated in two ways.
1) We demonstrate that two EGFR deletions commonly found in lung cancers are not present in tissue from four normal
human lungs (10
7 copies of gDNA each) or in blood samples from 10 healthy individuals (10
7 copies of gDNA each). This is
inconsistent, at least at an analytical sensitivity of 10
27, with the hypotheses of (a) hypermutation or (b) strong selection of
these growth factor-mutated cells during normal lung development leads to accumulation of pre-neoplastic cells with these
EGFR mutations, which sometimes can lead to lung cancer in late adulthood. Moreover, MAP was used for large scale, high
throughput ‘‘gene pool’’ analysis. No germline or early embryonic somatic mosaic mutation was detected (at a frequency of
.0.3%) for the 15/18 bp EGFR deletion mutations in 6,400 individuals, suggesting that early embryonic EGFR somatic
mutation is very rare, inconsistent with hypermutation or strong selection of these deletions in the embryo. 2) The second
illustration of MAP utility is in personalized monitoring of therapy and early recurrence in cancer. Tumor-specific p53
mutations identified at diagnosis in the plasma of six patients with stage II and III breast cancer were undetectable after
therapy in four women, consistent with clinical remission, and continued to be detected after treatment in two others,
reflecting tumor progression.
Conclusions: MAP has an analytical selectivity of one part per billion for detection of MIDIs and an analytical sensitivity of
one molecule. MAP provides a general tool for monitoring ultra-rare mutations in tissues and blood. As an example, we
show that the personalized cancer signature in six out of six patients with non-metastatic breast cancer can be detected and
that levels over time are correlated with the clinical course of disease.
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Introduction
The ability to detect exceedingly rare somatic mutations
associated with cancers will help elucidate mechanisms of
carcinogenesis and monitor early recurrent cancer in personalized
medicine.Spontaneousmutation frequencyisaslowas1610
28 and
2.1610
26 in human normal and cancerous tissues, respectively [1].
The analytical selectivity (see Terminology in Methods)o f
conventional sequencing or massively parallel DNA pyrosequen-
cing is currently one part in ten or one part in 100, respectively
[2]. Previous analytic methods generally have analytical selectiv-
ities of 10
2–10
3, with the exception of BEAMing and MutEx/
ACB-PCR for a limited subset of restriction sites [3,4]. Recently,
Pao and Ladanyi [5] compared 13 methods for detecting the
PLoS ONE | www.plosone.org 1 September 2009 | Volume 4 | Issue 9 | e7220common 15 bp epidermal growth factor receptor (EGFR) deletion
in lung cancers (including Loop-hybrid mobility shift assay,
Cycleave PCR, PCR-RFLP and length analysis, MALDI-TOF
MS–based genotyping, PNA-LNA PCR clamp, Scorptions
ARMS, Mutant-enriched PCR). Of these, the most sensitive
method, SMart Amplification Process, SMAP [6], had an
analytical selectivity of 1 in 10
3.
Pyrophosphorolysis-Activated Polymerization -Allele specific
amplification (PAP-A) is a sensitive and selective method for
DNA amplification to detect ultra rare mutations [7]. The method
utilizes allele-specific oligonucleotides that are blocked at the 39
end by a dideoxy nucleotide. These ‘‘sleeping beauties’’ are inert
until activated on their cognate template by the ‘‘kiss’’ of
pyrophosphorolysis, allowing extension to occur. PAP-A has a
potential analytical selectivity of 3.3610
11 because false positives
can occur only if two independent rare events occur in series:
mismatch pyrophosphorolysis and misincorporation (mis-polymer-
ization) at the first polymerized nucleotide (Fig. S1A). PAP-A has
an actual analytical selectivity of 10
4,10
5 because of polymerase
misincorporation within the extension product from the opposite
primer (bypass reaction) [7].
Bi-directional PAP-A (Bi-PAP-A) was developed to eliminate the
bypass reaction, and thereby increase analytical selectivity, by
using two blocked primers that overlap at one base [8,9] (Fig.
S1B). It has an analytical selectivity of .1610
7 for certain single-
base substitutions (G.C, C.G, A.T, or T.G). However, the
high baseline frequency of the deaminated cytosine and 8-oxo-
guanidine in genomic DNA limits the analytical selectivity of C.T
or G.T by Bi-PAP-A assays to .10
4 and .10
5, respectively.
When PAP-A primers are designed to detect microinsertions/
deletions/indels (MIDIs), the observed analytical selectivity is less
than one part in 10
5 for reasons that are unclear (Fig. S1C).
Therefore, we developed MIDI-Activated Pyrophosphorolysis
(MAP), a method with a MIDI analytical selectivity that is
generally 100,000 fold greater ($1610
9) than in PAP-A. MAP is a
seemingly simple modification of PAP-A in which the blocked
oligonucleotides (‘‘sleeping beauties’’) have multiple mismatches to
the wild type sequence. In MAP, false positives arise by the serial
coupling of a heteroduplex slippage event followed by pyropho-
sphorolysis of mismatched heteroduplexes. Unlike PAP-A, there is
no requirement for misincorporation.
WeillustratetheutilityofMAPforaddressingbiologicalquestions
by: i) testing the hypothesis that the common 15 and 18 bp
microdeletions in the EGFR gene in non-small cell lung cancers
derive from pre-neoplastic mutations selected during lung develop-
ment [10] and ii) monitoring of therapy and early recurrence
by detecting personalized cancer mutation signatures in the blood
of women with stage II and III breast cancers. Herein, we
demonstrate that analysis of plasma can reliably detect cancer
mutationsignaturesinsixwomenwithstage IIand IIIbreastcancer.
Methods
Terminology
MIDI. Microinsertion, deletion or indel; an insertion, deletion
or indel that results in a gain or loss of 1 to 50 nucleotides [11].
Pyrophosphorolysis. The removal of the 39 terminal
nucleotide by DNA polymerase in the presence of
pyrophosphate (PPi) to generate the nucleotide triphosphate.
Pyrophosphorolysis is the reverse of DNA polymerization.
MAP. MIDI- activated pyrophosphorolysis.
PAP. Pyrophosphorolysis-activated polymerization. Variants
of PAP include allele-specific PAP (PAP-A) and bi-directional PAP
(bi-PAP-A) [7].
Sleeping Beauties (P*). An oligonucleotide with a blocked
39 terminus that is not directly extendable but is activable by
pyrophosphorolysis [7] (see Fig.S1A).
Analytical Sensitivity. The minimum copy number of a
template that generates a detectable product when P* matches the
mutant template. It is determined by serial dilution of the mutant
DNA molecules.
Analytical Specificity. The maximum copy number of the
mismatched template that does not result in a detectable product
when P* mismatches the wild-type template. It is determined by
serial dilution of the wild-type molecules.
Analytical Selectivity. The ratio of analytical specificity to
analytical sensitivity.
Indel. A mutation resulting in a co-localized insertion and
deletion with a net gain or loss of nucleotides.
Tandem-base mutation (TBM). A mutation that results in
base changes at adjacent nucleotides [12,13].
Doublet. A mutant containing two nonadjacent mutations
[14].
Primer design and synthesis of P*
Standard primers were designed to amplify wild type or mutant
segments with Oligo 5 software (National Biosciences) (Table S1).
MAP primers. A pair of primers with similar Tm values,
each about 30 bases in length and separated by a 50,300 bp
sequence segment, was designed for each MAP assay to detect
rare deletions. Each P* primer was modified by adding
a dideoxynucleotide at the 39 terminus as described previously
[15]. The mutation-specific primer mismatched the wild type
sequence at two to six bases, but matched the mutant sequence at
these positions (Fig. 1A). For detecting a mutation in plasma, the
size of the amplicon should be ,100 bp because plasma DNA is
highly degraded.
Primers for site-directed mutagenesis. To generate
mutant templates to use as positive controls, a mutation-specific
primer is composed of 45-mers of mutant sequence with 10–15
nucleotides complementary to wild-type sequence at the 39 termini
for annealing to the wild-type template [16].
Preparation of templates for MAP for testing analytical
specificity and analytical sensitivity
Normal genomic DNA was isolated from blood in healthy
relatives of patients with hemophilia by Puregene Genomic DNA
Purification Kit (Gentra Systems, USA) and corresponding wild
type segments of EGFR (NM_005228.3) and EGFR2
(NM_001005862.1) were amplified. Mutant genomic DNAs were
isolated from lung tumors that had been sectioned and
microdissected as described previously[17]. Standard extraction
protocols were optimized for low levels of DNA. Carrier nucleic
acids are utilized to avoid losses due to absorption.
Four DNAs with different EGFR mutations [two with the
common deletions (c.2235_2249del15 and c.2240_2257del18),
one with a tandem base mutation (TBM; see Terminology in
Methods) and one with a doublet] were amplified with standard
primers. The artificial 14 bp deletion in exon3 in the human
EGFR gene was generated by site-directed mutagenesis PCR to use
in ‘‘control’’ assays. The assays for the rat EGFR (NM_031507.1)
15/18 bp deletions and EGFR2 (NM_017003.2) 15 bp deletion
were designed based on the homologous region in human EGFR
(Table S1).
The above PCR products were cloned with TOPO TA Cloning
kit (Invitrogen Life Technologies). Plasmid DNA with the inserted
amplicon was confirmed by sequencing in both directions.
Plasmids containing the wild-type sequence served as the template
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sequence served as the template for the analytical sensitivity test.
The other positive templates with a length of 100 bp were
synthesized by Sigma Company. Wild type and mutant DNAs
were cloned sequentially and separately to avoid cross contami-
nation. An analytical sensitivity assay was performed by adding a
series of dilutions of 100, 10, 4, 2, 1, 0.5, 0.25 copies of subcloned
mutant DNA (human or rat) or synthesized oligonucleotides.
Analytical specificity was determined by adding a series of
dilutions of 10
10,1 0
9,1 0
8,1 0
7,1 0
6,1 0
5,1 0
4 copies of
correspondingly subcloned wild-type DNA (human or rat).
MAP reaction
The MAP reaction mixtures consist of 50 mM Tris-HCl
(pH: 7.8, 25uC), 16 mM (NH4)2SO4, 1mM DTT, 1.5 mM
MgCl2,9 0mM PPi, 100 mM P*, 4%DMSO, 25 mM dNTP, 4 U
Figure 1. A: MAP: Introducing multiple oligonucleotide mismatch into the 39 end of a mutation-specific blocked primer. An example
of a deletion mutant sequence (the common EGFR 15 bp deletion) is shown below the wild-type sequence (deleted sequence in brackets, red letters).
The last three bases (39) of a mutation-specific 39 blocked primer (upstream) are complementary to the three bases (caa) just before the 59 end of the
deletion; the primer mismatches the wild-type sequence at the three bases (agc) at the 39 end of the deleted region. Asterisks indicate the 39
dideoxynucleotide of the blocked primers. The ‘‘X’’ represents mismatch between the mutant-specific primer and wild-type sequence. B: Serial
coupling of two errors underlies the ultra-high analytical selectivity of PAP and MAP. PAP-A or Bi-PAP-A and MAP derive their high
analytical selectivity from serial coupling of two events, but the events differ. The practical analytical specificity for PAP-A and Bi-PAP-A is limited by
side reactions such as misincorporation from the extended generic PAP primer or the presence of DNA damage products such as deaminated
cytosine or 8-oxo guanidine. In contrast, false positives in MAP require the serial coupling of DNA slippage and mis-pyrophosphorolysis within this
distorted DNA structure.
doi:10.1371/journal.pone.0007220.g001
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gDNA carrier. The cycling conditions were 94uC for 20 seconds,
60uC for 30 seconds, 64uC for 30 seconds, 68uC for 30 seconds,
72uC for 30 seconds, for a total of 50–55 cycles. In addition, 94uC
for 2 minutes was used for the initial denaturation and 72uC for 7
minutes for the last extension. Reaction products (5 ml) were
electrophoresesed through a standard 2% or 4% agarose gel with
ethidium bromide. The gel was photographed under UV light by a
CCD camera. The products were also submitted for sequencing
for confirmation of the mutation (data not shown). Hot-start MAP
was performed with Mag Hotbead (KK Biomed Corporation, Salt
Lake City, Utah) to elevate the analytical selectivity of the reaction.
Control for contamination and inhibition
In order to avoid PCR contamination [18,19], reagents were
divided into aliquots and reactions were set up in a SterilGard II
hood. Seven parallel negative controls without a DNA template
were assayed to rule out the possibility of contamination of the
highly sensitive MAP assays. Mushroom DNA was extracted and
then amplified simultaneously to test for contamination during
DNA extraction.
To exclude the possibility of an inhibitor in the tested DNA, two
positive controls containing the same amount of tested DNA were
spiked with 10 or 4 copies of the mutant, and were amplified
simultaneously to confirm that one mutant molecule can be
amplified in the presence of 1.7–3.3 mg DNA (0.5–1610
6 copies of
genome). The QIAamp DNA mini-kit was chosen due to its ability
to remove inhibitors.
Quantitative MAP based on Poisson distribution
Multiple parallel reactions (10–20) are performed per sample.
Some of the parallel reactions may be negative because of no
mutant template. Every positive reaction is regarded as being
derived from one or more copies of mutant templates. Based on
Poisson distribution, the expected average number of mutant
templates per reaction is estimated using a formula (Poisson
distribution) f(0)=e
2x, where x is the average number of mutants
per reaction [7]. The mutation frequency is calculated as the
number of mutants (the average number of mutants 6 the total
number of reactions) divided by the approximate total number of
copies of genomic DNA contained in the 10–20 reactions per
sample or per ml plasma.
Reconstruction experiments
The human EGFR 15 bp deletion served as a model to
investigate the relationship between the number of mismatched
nucleotides and MAP analytical selectivity. To determine
analytical sensitivity and analytical specificity, reconstruction
experiments were conducted with 3.3 mg mouse genomic DNA
(1610
6 copies of genomic molecules with or without spiked mutant
DNA). We previously demonstrated that analytical sensitivities
were similar in reconstruction experiments in the presence of 3.3
mg of human genomic DNA from cells containing the mutation of
interest [9].
Detection of EGFR deletions in normal human lung by
MAP
Anonymized human lung tissues were obtained utilizing City of
HopeIRBprotocol01200fordiscard samplestobeused inmethods
development and research. All four of the autopsy lung samples
were obtained from patients with leukemia. DNA from blood
samples from ten healthy relatives of patients with hemophilia,
previously used for a different study, was also tested under the
approved IRB 01200 discard sample protocol. The EGFR 15 and
18 bp deletions in exon19, a 14 bp artificial deletion in exon 3, and
an EGFR2 15 bp homologous deletion were analyzed in the normal
lung tissue and blood by MAP. Twelve or twenty-two parallel
amplifications, containing a combined total of 10
7 molecules of
genomic DNA, were conducted simultaneously with analytical
sensitivity assays, positive controls, and multiple negative controls.
Detection of EGFR deletions in normal rat lung by MAP
For rat tissues (Fisher), the 15 and 18 bp deletions in the rat
EGFR gene homologous to the human EGFR gene were analyzed
in normal lung and liver tissues from 5 adults. The homologous
15 bp deletion in EGFR2 exon 20 was used as a control in rat lung
and liver tissues, as well as an artificial 15 bp deletion in EGFR2
exon19. The primers used are shown in Table S1.
Somatic mosaicism of the EGFR 15/18 bp deletions
tested by ‘‘gene pool’’ analysis
DNA samples from leukocytes of 400 healthy individuals were
pooled together as a group with an aggregated concentration of
200 ng/ml. MAP was utilized to detect the EGFR gene 15/18 bp
deletions in 16 such groups, for a total of 6,400 individuals. Four ml
of DNA per group was used in MAP assays; e.g., mosaics at a
frequency of 1 in 300 cells were tested (2 ng DNA/individual).
Monitoring of early recurrence of breast cancer by cancer
signature mutation
Blood samples (15 ml) were collected from six patients with
breast cancer and tested at intervals over a number of time points,
including before therapy, before and after three cycles of adjuvant
chemotherapy, just prior to surgery, and at 3, 6, 9, and 12 months’
follow-up after surgery. Each patient was tested at 3 to 9 different
time points over this period and followed in total for an average of
about 11 months (range 8–17 months). Each patient is a
participant in a City of Hope Cancer Center IRB-approved
clinical trial, protocol 05015; all patients signed an informed
consent for the use of their samples.
Plasma was separated from fresh or previously frozen blood by
centrifugation. The amount of plasma obtained from frozen blood
after removal ofblood cells isequivalent to half the amount obtained
from fresh blood. DNA from 1–3 ml plasma was extracted by
QIAamp DNA Micro kit (Qiagen Inc.) with an addition of carrier
RNA. DNA from blood cells was extracted by QIAamp Blood DNA
Maxi Kit (Qiagen Inc.). The mutation test was performed on 1610
7
copies of genomic DNA from blood cells (about 1 ml blood).
Results
MAP increases analytical selectivity 100,000-fold
The common 15 bp or 18 bp deletions in the epidermal growth
factor receptor (EGFR) gene, commonly found in 5–20% of
patients with non-small cell lung cancers [10], were chosen as
models to explore the analytical sensitivity and analytical
selectivity of MAP. In MAP, both downstream and upstream
primers are blocked with a dideoxynucleotide (P*) and separated
by 50 to 300 bp. The mutation-specific primers match the mutant
and overlap the deletion junction so that two or more nucleotides
mismatch the wild type sequence (Fig. 1A). When mutant-specific
primers for the 15 bp deletion contain multiple mismatches (2–5
bases) with the wild-type template, the analytical selectivity of the
assay is .10
9 (Fig. 2B–D, Table S2) and 100,000-fold greater than
that observed in PAP-A, which contains only one base mismatch
at the 39 end (analytical selectivity #10
4) (Fig. 2A).
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mismatched nucleotides
The analytical sensitivity of detection in the MAP assay is one
molecule for all assays (Fig. 2B–G). The Poisson nature of the
serial dilution profiles (see Methods) supports the accuracy of
copy number quantitation; e.g., sometimes 1 copy number does
not amplify, whereas K or J copy number does. Figure 2
provides an example of this. MAP can reproducibly amplify single
molecules to ,200 ng product in the presence of carrier genomic
DNA or RNA by an estimated four trillion-fold without nesting.
This yield is at least 100-fold better than routine PCR, presumably
because the MAP primers are inert until activated and extended
on their cognate template.
The analytical selectivity of one, two, three, five, seven, eight and
nine mismatched nucleotides was tested (Fig. 2A–G, Table S2).
Analytical selectivity is optimal with mismatches of 2 to 5
nucleotides (Fig. 2B–D). Analytical selectivity decreased dramati-
cally with 7 or more mismatches. Since activation of P* can be
inhibited even by single base mismatches up to 15 nucleotides from
the 39 end [15], it was hypothesized that the loss of analytical
selectivity is due to the ability of trace amounts of unblocked
oligonucleotides to artificially create the deletions by looping out the
15 nucleotides in wild-type DNA with increasing frequency as the
heteroduplex of primer and loop-containing wild-type template is
stabilized by longer strings of matching nucleotides beyond the
deletion site (Fig. S2). Consistent with this hypothesis, i) hot-start
MAP increased the analytical selectivity of the eight nucleotide
mismatches from .10
4 to .10
6 (data not shown); and ii) sequence
analyses indicate that the false positives with a PAP-A assay for a
15 bp deletion were due to one base misincorporation (Fig. S2 A)
while the false positives with MAP were consistent with slipped
heteroduplexes and mismatch pyrophosphorolysis (Fig. S2 B–D).
MAP assay analytical selectivities generally are .10
9 and
analytical sensitivities are one molecule
The MAP analysis of other deletions in the EGFR, EGFR2 and
p53 genes in human or rat demonstrated analytical selectivities
.10
8–10
9 when P* mismatched the wild type sequences by 3–5
Figure 2. MAP analytical selectivity is related to the number of mismatched nucleotides using the EGFR 15 bp deletion as a model.
The analytical selectivity of MAP is higher than 1610
9 when the number of mismatched nucleotides is 2–5, but sharply lower when the number of
mismatched nucleotides is 7 or more. Analytical Sensitivity: Mutant DNA is serially diluted to 100, 10, 4, 2, 1, 1/2, 1/4 copies of template. The analytical
sensitivity of the reaction is the minimum copy number of a mutant DNA that generates a detectable product when the primer matches the mutant
template. The absence of a signal at one copy and the presence of a signal at K or J copy are consistent with the Poisson distribution of expected
signal resulting from dilution of DNA. Analytical Specificity: Wild type DNA is serially diluted from 10
10 to 10
3 copies. The analytical specificity of the
reaction is the maximum copy number of the mismatched (wt) template that does not result in a detectable product when the primer mismatches
the wild-type template. Analytical selectivity is the ratio of analytical specificity to analytical sensitivity. Negative controls do not contain targeted
DNA. M: FX174 DNA/HaeIII Marker.
doi:10.1371/journal.pone.0007220.g002
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had analytical selectivities .10
9 and one assay with six mismatches
had an analytical selectivity .10
8. MAP was also demonstrated to
detect four additional types of mutations with multiple base
mismatches with respect to the wild type sequence. The analytical
selectivity of MAP was .10
10 for an insertion, .10
9 for a tandem
base mutation and for two indels, and .10
8 for a doublet (two
single base substitutions separated by 5 bases) (Fig. 4, Table S3).
A significant fraction of doublets, those closely clustered, can be
assayed with high analytical selectivity by MAP [14]. For the
EGFR doublet mutation at 2574 T.G and 2580 A.T, the
analytical selectivity is 10
8. This reflects the inhibition of P*
activation by a mismatch six bases downstream from the 39 end,
consistent with previous data that mismatches far away from the 39
end substantially inhibit the activation of P* [15]. Altogether, 15
MAP assays with 2–6 bp mismatches provided an analytical
selectivity .10
8–10
10 and an analytical sensitivity of one molecule
to detect MIDIs (Tables S2, S3).
Proof of Principle: Direct analysis of in-vivo tissue
mutagenesis – EGFR 15 and 18 bp deletions are not
found in 8610
7 normal human lung cells
Until now, specialized genetic constructs such as Big Blue mice
or selective medium that can identify mutations in limited cell
types have been required for direct examination of in vivo
mutagenesis in tissues. MAP assays can allow MIDIs to be
analyzed directly in the species of interest. In an illustrative
application, we tested as a hypothesis of interest that the EGFR 15/
18 bp deletions found in 5–20% of non-small cell lung cancers
might have arisen during the development of normal lung tissue
and been enriched due to a selective replication advantage [10].
The common 15/18 bp EGFR deletions were not observed in a
total of 8610
7 genomes from normal human adult lung (4 normal
lung samples610
7 copies of gDNA per sample62 assays for each
lung) or in a total of 2610
8 genomes from the blood of normal
individuals (10 blood samples 610
7 copies of gDNA per sample
62 assays for each blood sample) (Fig. S3, Table S4). The
analogous EGFR2 gene 15 bp deletion in exon19 and an artificial
14 bp deletion in EGFR exon 3 were not detected in a total of
1.4610
8 genomes (10 blood samples 610
7 copies of gDNA per
sample +4 lung samples 610
7 copies of gDNA per sample).
Controls spiked with each of these two deletion mutations
demonstrated that one mutant molecule can be detected in 1.7–
3.3 mg gDNA (0.5–1610
6 genomes) and that the samples lacked
inhibitors at the concentrations of genome utilized. No false
positives were detected in multiple negative controls (no template
DNA; mushroom DNA) showing that no contamination occurs
during PCR set-up or DNA extraction.
Proof of Principle: Direct analysis of in-vivo tissue
mutagenesis – EGFR 15 and 18 bp deletions are not
found in 5610
7 normal rat lung cells
Recently, EGFR mutations in the kinase domain (exons 18–21)
were also found in 14% of lung adenomas/adenocarcinomas from
FEN1 mutant knock-in mice [20]. For the rat, MAP assays were
developed for the EGFR 15 and 18 bp deletions homologous to
those found in human. The EGFR 15 and 18 bp deletions in rat
were not found in 10
7 genomes from 5 normal rat lungs (5610
7
cells, in total) and livers, nor was a 15 bp deletion in rat EGFR2
(homologous to the rat EGFR 15 bp deletion region) (Table S4).
Figure 3. MAP detects deletions in human DNA with an analytical selectivity .10
8. Four assays were established to test the MAP analytical
sensitivity and analytical specificity (labeled by copy number). The analytical sensitivities of each assay are one copy and analytical specificities are
.1610
8 copy. From top to bottom panels, primer mismatches with the wild type template were 4, 4, 4 and 6 nucleotides, respectively. The presence
of a signal at a mean of one copy of the mutant template is predicted to be 63% based on the Poisson distribution due to random sampling,
consistent with the absence of signal in some reactions with one copy of mutant template.
doi:10.1371/journal.pone.0007220.g003
Cancer Mutation Signatures
PLoS ONE | www.plosone.org 6 September 2009 | Volume 4 | Issue 9 | e7220Proof of principle: High throughput population screening
for germline and early embryonic cancer syndrome
mutations
A family with a germline missense mutation in EGFR has a
dramatic lung cancer phenotype [21]. An individual mosaic for an
EGFR mutation may be at increased risk for lung cancer. If the
EGFR deletions were hotspots of mutations by a novel mechanism,
they may be predisposed to occur early in embryogenesis. Such
individuals might be at an increased risk for lung cancer, but the
mutation would not be detected by conventional screening
methods.
Sixty-four hundred unrelated control DNA samples (86.8%
European Caucasians, 4.3% Hispanics, 2.2% Asians, 2% Blacks,
2% Mestiza Columbian, 0.8% American-Indians, and 1.9% of
unknown ethnicity) available in the laboratory were analyzed with
MAP for the two common 15/18 bp deletions [22]. Samples were
diluted to 200 ng/ml. These samples were pooled into groups of
400 individuals. 800 ng of genomic DNA were analyzed per pool
(600 genomes per individual). No germline or mosaic mutation for
any of the tested EGFR mutations was found in ‘‘gene pool’’
analysis with MAP (Fig. S4).
Proof of Principle: Personalized monitoring of disease
recurrence or therapy in the plasma and cellular
components of blood – Cancer mutation signatures
detected in six patients with non-metastatic breast
cancer
MAP may be used for monitoring of therapy or recurrence of
cancer in the cellular and plasma compartments of blood by using
the mutation signature of the tumor. Analysis of tumor biopsy
tissues from a woman with stage II breast cancer who underwent
three cycles of neoadjuvant chemotherapy with doxorubicin,
docetaxel, and cyclophosphamide (TAC) revealed a 3 bp somatic
insertion in the p53 gene (c.720_721insAGT, p.240dupS). A MAP
assay was designed to determine whether the 3 bp insertion could
be detected as a personalized marker for the tumor. The analytical
sensitivity was one molecule and the analytical selectivity .1610
10
(Fig. 4A). The cellular compartment of blood was analyzed as an
indicator of circulating tumor cells and the plasma was analyzed as
an indicator of apoptotic/necrotic cancer-shedding membrane-
encapsulated short DNA fragments in the circulation [23,24].The
mutationfrequencywasestimatedatabout4 moleculespermilliliter
of plasma at pretreatment and within 24 hours after first treatment.
After completion of neoadjuvant therapy, breast preserving surgery
failed to demonstrate any pathological evidence of remaining
tumor. The tumor-specific mutation became undetectable prior to
the second cycle of neoadjuvant chemotherapy and remained
undetectable at nine subsequent time-points spanning12 months of
follow-up (Fig. 5, Table 1), consistent with the absence of clinical
recurrence. The MAP assay was reproducible. Three independent
DNA extractions and assays yielded the same results. The MAP
assays were performed without knowledge of the clinical phenotype:
Stage II disease, about 3.5 cm of tumor pre-therapy (Table 1), good
response to neoadjuvant chemotherapy and continued remission at
13 months post diagnosis.
Another patient, who had stage III inflammatory breast cancer,
was found to harbor a 2 bp deletion (c.165_166delTG) within the
p53 gene. The three blood samples available revealed the cancer
signature in both the blood and cellular compartments (Table 1).
Figure 4. MAP detects insertions and complex mutations with an analytical selectivity .10
8. The analytical selectivity of MAP for
detecting an insertion in the p53 gene (A) and complex mutations in the EGFR gene (B–E) is greater than 1610
8 in five different assays. In each assay,
the primer contained 2–4 mismatches with the wild type sequence. The mutations detected were the following: P53 gene: (A) Duplication:
c.720_721insAGT; EGFR gene: (B) Tandem-base mutation: c.2154G.T, 2155G.T; (C) 2–18 Indel: c.2239–2258delinsCA; (D) 5–17 Indel: c.2237–
2253delins TTGCT; (E) Doublet: c.2574T.G, c.2580A.T.
doi:10.1371/journal.pone.0007220.g004
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per ml of plasma and persisted at 3 weeks after surgery and at the 3
month follow-up. Despite the large tumor load, there was very little
mutation signature in the cellular compartment compared to the
plasma compartment (Table 1). Indeed, some or all of the mutation
signature in the cellular compartment may reflect contamination
from plasma, i.e., about 1% plasma contamination in the buffy coat
fraction could account for the cellular compartment values seen.
Pathologic assessment of the patient’s mastectomy specimen
following neoadjuvant therapy revealed that virtually the entire
breast mass consisted of malignant cells, indicating minimal
response to neoadjuvant therapy. Shortly after surgery, metastases
were found. The patient died of progressive disease.
In addition to these two patients, four others with stage II or III
breast cancer had tumor-specific p53 mutations identified and
MAP assays developed for their analysis in blood (Table 2,
Supplementary Fig.S5). In total, four of the six patients (ID # 1, 3,
4, 6) had detectable levels of tumor-specific mutation in plasma at
diagnosis, but the levels fell to zero after therapy resulting in
clinical remission. However, the cancer mutation signature was
present, even after therapy, in all samples from two other patients
(ID # 2 and 5), reflecting tumor progression.
Discussion
MAP, a highly sensitive assay for ultra-rare mutations, enhances
the detection of MIDIs by using multiple oligonucleotide
mismatches, enabling detection generally at one part in a billion.
False positives seem to arise by the extremely rare serial coupling
of two events: slipped heteroduplex formation and mis-pyropho-
sphorolysis within a distorted heteroduplex. The practical outcome
is robust and routine detection of ultra-rare MIDIs and complex
mutations with an analytical selectivity generally .10
9 and an
analytical sensitivity that is generally one molecule. MAP was
found to be methodologically robust when utilized i) to detect
EGFR mutations in lung tissue or ii) to detect p53 breast cancer
signatures in plasma and the cellular compartments of blood or iii)
to screen for mosaicism for common EGFR mutations in a large
population.
Three methods now provide a complete ultra-rare mutation
detection platform: classic PAP-A for any type of mutation, Bi-
PAP-A for single base substitutions, and MAP for MIDIs. A
summary of the three methods, including their analytical
selectivities and the types of mutations for which they are most
useful, is shown in Table S5.
MAP Assay: Limitations
The MAP assay is by far the most sensitive assay described thus
far for detecting MIDIs. In the analytical specificity assays,
however, there are technical limitations in using human genomic
DNA. For example, 10
9 copies of human genomic DNA is
equivalent to 3,300 mg DNA, which requires a large amount of
tissue. Addition of this quantity of DNA is not feasible for a typical
Figure 5. Cancer signature mutation was identified in 0.5 ml plasma at pretreatment and within 24 hours of initial chemotherapy in
a patient with non-metastatic breast cancer. The MAP analytical sensitivity is demonstrated to be one copy. The positive controls (10+ and 4+)
show no inhibitor when 10 or 4 copies of mutant templates are added to plasma DNA derived from A. Blood samples were obtained at the following
times: A, B: at pretreatment and within 24 hours after cycle 1 chemotherapy. C, D: at pretreatment and within 24 hours after cycle 2 chemotherapy. E,
F: at pretreatment and within 24 hours after cycle 3 chemotherapy. G, H: at midtreatment and within 3 weeks after surgery. Lane I is a control assay
using crab gDNA extracted simultaneously with plasma to rule out contamination occurring during DNA extraction. For each time point, multiple
duplicate reactions were performed (see Table 1). Only two reactions per time point are shown in this Figure.
doi:10.1371/journal.pone.0007220.g005
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constructed a plasmid (4,5 kb) containing a 300,400 bp
segment identical to the human genomic DNA region of interest;
the copy number for the wild-type sequence can now be elevated
to 10
11 per ml along with 10
6 copies of total wild type genomic
DNA. At least 10
9 copies of genomic DNA is a preferable
Table 1. Cancer mutation signature can be reproducibly detected in blood in patients with stage II or III breast cancer.
Plasma Cellular fraction
Time-points
a Course Days
Plasma
Volume
(ml)
Mutation
signature per
reaction
c
Mutation
frequency (per
ml plasma)
Blood volume
ml (molecules
DNA)
Mutation
signature per
reaction
Mutation
frequency
(per ml blood)
Case-1
b
1 pre-treatment 0 3 7/11 (1.01)
d 3.7 1 (1610
7) 0/20 0
2 cycle 1(post) 1 3 9/13 (1.18)
d 5.1 1 (1610
7) 0/20 0
3 cycle 2 (pre) 18 3 0/13 0 1 (1610
7) 0/20 0
4 cycle 2 (post) 19 3 0/13 0
5 cycle 3 (pre) 39 3 0/13 0
6 cycle 3 (post) 40 3 0/13 0
7 mid treatment 60 3 0/13 0
8 3 weeks after surgery 128 3 0/13 0
9 3 month F/U 218 1 0/2
e 0
10 6 month F/U 308 1 0/4
e 0
11 9 month F/U 398 1 0/2
e 0
12 12 month F/U 488 1 0/2
e 01 ( 1 610
7) 0/20 0
Case-2
b
1 pre-treatment 0 0.01 2/10(0.223)
d 223 1 (1610
7) 2/20(0.105)
d 2.1
2 3 weeks after surgery 138 0.01 2/10(0.223) 200 1 (1610
7) 5/20(0.288) 5.8
3 3 month F/U 228 0.01 1/10(0.105) 105 1 (1610
7) 2/20(0.105) 2.1
a: Blood samples 1–8 and 10 in case-1 and 1–3 in case-2 were frozen, thawed, and centrifuged. DNA was extracted from the cell pellet and from the supernatant, which
contained plasma and lysed red cells. Blood cells for time points 9, 11, and 12 were centrifuged when fresh and the plasma was removed.
b: The patient (case-1 with c.720_721insAGT in p53 gene) remained disease free at the end of follow-up. The other patient (case-2 with c.165_166delTG in p53 gene)
died of progressive disease.
c: The number of positive signals appearing in the total number of MAP reactions per time point.
d: The expected average number of mutants per reaction is estimated using a formula (the frequency of zero mutants per reaction=e
2x, where x is the average number
of mutants per reaction), assuming that: the mutant distributes in the reaction according to a Poisson distribution; if one or more mutants are in the reaction, the
amplification is positive; and if zero mutants are in the reaction, it is negative.
e: Follow-up assays were performed with 1 ml plasma instead of 3 ml, as in the earlier assays. Fewer reactions were run, perhaps decreasing the analytical sensitivity of
the measurement.
doi:10.1371/journal.pone.0007220.t001
Table 2. The correlation of the copy number of cancer mutation signature and tumor load at diagnosis.
Patient ID Stage Size by RECIST criteria p53 gene mutation
Copy number of
mutation signature
per ml plasma
Copy number of mutation
signature in cellular
compartment per ml blood
1
a Stage II R: 3.5 cm c. 720_721insAGT 4
b 0
2
a Stage III R 12 cm mass and 4 cm lymph in
inflammatory breast cancer
c. 165_166delTG 223 2
3 Stage III 5.5 cm L breast/multiple nodes c. 642_643delTA 10
b 0
4 Stage III L 2 cm and 2.8 cm lymph node and
inflammatory breast cancer
c. 581T.G9
b 3
5 Stage III L 6.5 cm cancer and 2.8 cm lymph node
in axilla with several others
c.216_217insC 600 NA
6 Stage III L 6.6 cm cumulative (multifocal) with 1.8
cm lymph node and other nodes
c. 723delC 6
b NA
aAdditional information about patients 1 & 2 is described in Table 1 (Cases 1 & 2).
bThe cancer mutation signature decreased to 0 per ml plasma during therapy resulting in clinical remission.
cAbbreviations: NA- not available; L- left breast; R- right breast.
doi:10.1371/journal.pone.0007220.t002
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However we note that certain human sequences are present
within these reconstruction experiments at 10
12 copies without
interference with PAP analytical selectivity.
Hypothesis to explain the high frequency of the three
common EGFR somatic mutations observed in lung
cancer
The approximately four trillion cells in adult lung contain
essentially every possible mutation; depending on the base pair,
frequencies typically range from 10
27–10
210. Our hypothesis
states that the three EGFR mutations commonly seen in lung
cancer (L858R and the 15 bp and 18 bp deletions), which
comprise .80% of all EGFR mutations seen in lung cancer,
occur due to selection of cells with these mutations during lung
development, resulting in greatly increased frequencies of these
mutations compared to similar types of non-selected mutations in
EGFR and other genes.
MAP in lung DNA: EGFR mutants are not detected by
MAP in normal human or rat lung cells
The EGFR (exon 19) 15 bp or 18 bp microdeletions are
commonly found in 5–20% of patients with non-small cell lung
cancers [10]. As lung cancer accounts for about 1/3 of all cancer
deaths, these deletions are involved in about 1.5–6% of all lethal
cancer events. Neither the mutation mechanism nor the
mechanism of oncogenesis of these frequent mutations is
understood.
The sequence context of these deletions does not suggest an
endogenous hotspot [25]. These deletions could be a mutation
signature from some as yet unknown mutagenic agent. Alterna-
tively, these somatic deletions could be rare events that occur early
in lung development and that are then enriched due to a selective
advantage, as observed in other systems [10,26,27]. The above
hypotheses would predict that these deletions are potential cancer
driver mutations rather than passenger mutations, and that
normal lung may contain these deletions at some low frequency.
Neither of the EGFR microdeletion mutations was detected in a
total of 8610
7 genomic DNA copies in four normal human lungs
or in a total of 2610
8 genomes in blood samples from 10 healthy
patients, suggesting that the hypotheses are incorrect, at least at
the mutation frequencies tested. Homologous deletions in similar
copy numbers of genomic DNA from five normal rat lungs were
also not detected. Additionally, no germline or mosaic mutation
for any of the tested EGFR mutations was found in ‘‘gene pool’’
analysis with MAP. The data indicate that these deletions are
unlikely to occur during embryogenesis or lung development.
These results do not support the hypothesis of mutational
mosaicism, followed by enrichment by selection.
Note that the hypothesis could still be correct if the frequency of
the deletions was 10
210 and the enrichment was 500-fold, such that
the mutations would be below the detection threshold of the
experiment. The analytical selectivity of MAP would allow these
hypotheses to be tested further by analyzing larger amounts of
sample. Most pediatric leukemias are initiated in utero [26,28]; it still
remains possible that certain adult tumors could be initiated in utero.
MAP in blood from women with breast cancer:
Personalized tumor-specific cancer signatures are
detected in six of six patients with non-metastatic breast
cancer and their levels reflect disease course
Among several reported studies in colorectal cancer, lung
cancer, and ovarian cancer patients, a tumor-specific p53 mutation
was detected in an average of 40%, 75%, and 26%, respectively, of
the corresponding plasma samples (Table 3, Table S6). In the
present study, the detection of p53 tumor-specific mutations in
plasma DNA samples from 100% of patients (6/6) with non-
metastatic breast cancer is significantly higher than those observed
in colorectal cancer (p=0.006) and ovarian cancer (p=0.007).
However, the plasma levels of the lung cancer tumor signature
seem generally higher, as about 75% were detected by SSCP or
sequencing.
The levels of plasma mutation signature depend on the rate
at which tumor necrosis and apoptosis occur, the rate at which
protected DNA fragments are generated, and the rate at which
these are cleared from the circulation. Patient- or tumor-
specific differences are possible, complicating the relationship
between tumor mass and the molecules of the cancer signature.
For a given tumor in a given patient, the tumor signal in blood
may be proportional to tumor burden, unless drug therapy
confounds the risk of tumor apoptosis/necrosis. Future studies
with careful quantitation of tumor mass are needed to clarify
these issues.
To detect the cancer signature in 10
7 genomes (3.3 mg genomic
DNA per tube x 10 tubes) requires an analytical selectivity of 10
8
or 10
9 if the false positive rates are to be kept at 10% or 1%,
respectively. The MAP assay is exquisitely selective for MIDIs and
other complex mutations. In the study herein, the level of mutant
p53 molecules (within a background of wild type p53 molecules) in
four of the six plasma samples was very low (Table 2) and would
not be detectable by most of the common methods of analysis.
Within the limits of sample size and unidimensional estimates of
tumor sizes, the signal corresponds very roughly to the ratio of
tumor load to body weight, as might be expected if plasma
shedding due to apoptosis/necrosis was roughly similar to normal
cells. Among the six patients in this study, initial plasma cancer
mutation signature levels per ml varied 150-fold. The variation is
not well correlated with tumor size, e.g., 100-fold variation in
plasma levels occurs in two tumors of 6.5 centimeters in one
dimension. However, the standard measure of tumor size, which is
used for the RECIST criteria [29], is one dimensional and may
well not reflect tumor volume accurately. A tumor-specific
mutation signature was detected in the initial plasma samples
from all patients, but in the cellular compartment of blood in only
two patients, one of whom subsequently developed metastatic
disease (Patient 2). It remains to be determined whether detectable
cellular cancer mutation signature is an indicator of particularly
poor prognosis.
Caveats to the correlation of the tumor-specific signal in
plasma or the cellular compartment of blood with the actual
tumor burden in the patient are (i) the possible underestimation
of the tumor burden if the somatic tumor mutation is present
only in some regions of the tumor and (ii) overestimation of the
tumor burden if occasional somatic mosaicism occurs in normal
tissue. Analysis of three to four tumor-specific somatic mutations
will be helpful to rule out signal deriving partially from non-
neoplastic cells or from somatic mutations present in only a
subset of the neoplasm. However, microdissection and sequenc-
ing of breast cancer samples suggest that p53 mutations are
generally, if not virtually always, clonal within breast cancer
[30,31].
Personalized Monitoring for early recurrence in cancer
Personalized monitoring for tumor response in the neoadjuvant
and advanced setting, as well as for detection of early recurrence,
may help optimize treatment by assessing the tumor signature in
the cellular and plasma components of blood over time. Such
Cancer Mutation Signatures
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ment, especially in the adjuvant setting. It may allow response to
therapy to be assessed and semi-quantitated in a manner superior
to that achievable by imaging. Bi-PAP-A and especially MAP
provide the technology for routinely accessing ultra rare mutations
in the cellular and plasma components of blood. While it is
possible that confounders of the measurement may limit its clinical
utility, the tools are now available to make the clinical
measurements. Such monitoring could be of help for treating a
variety of adult and pediatric tumors. For example, in childhood
cancers such as Ewing’s sarcoma and rhabdomyoscarcoma,
aggressive therapy can cure about 70% of patients, while toxicity
claims another 10% and recurrence the remaining 20%. Roughly
1/3 of patients are appropriately treated and the remaining
patients are either over-treated or under-treated.
MAP in population screening: Screening to identify
individuals with germline or mosaic mutations
predisposing to disease
Preventive medicine promises to reduce the cost of healthcare.
Below, we suggest that a national investment in generating pools of
DNA from millions of individuals could provide a national DNA
resource for effective mass population screening. We conclude that
MAP, PAP and Bi-PAP-A may utilize this resource to facilitate
cost-effective preventive medicine, e.g., see below.
MAP and PAP are synergistic. A duplex MAP assay for the
common 15 and 18 bp deletions was performed as proof of
principle of the multiplexing potential of MAP assays (data not
shown). PAP assays have previously been shown to multiplex with
sufficient rigor for dosage analysis [35]. MAP and Bi-PAP-A have
the potential to screen for a cocktail of mutations in large
populations for which early embryonic mutations (mosaicism) as
well as germline mutations could be detected. Since P* primers
generally do not form primer dimers in solution, highly
multiplexed PAP reactions for hundreds or even thousands of
specific mutations may be possible in solution. Additionally,
microarrays may facilitate multiplexed amplification. Bi-PAP-A
and MAP assays can work synergistically within one cocktail to
detect point mutations and deletions/insertions/indels with ultra
high analytical selectivity.
We present proof of principle that MAP/PAP cocktails have the
potential for highly efficient screening for mosaicism. Inheritance
of germline mutations in more than 2,800 genes cause document-
ed genetic disease (see OMIM database: http://www.ncbi.nlm.
nih.gov/omim/). Milder forms of these diseases can occur in
mosaic individuals who have experienced a relevant mutation very
early in embryogenesis. As illustrated by our analysis of two
common mutations in the EGFR gene, we screened 800 ng of
genomic DNA per pool (600 genomes per individual) in a pool of
400 individuals. Since a single cell contains 6.6 pg DNA (2
genomes), a mosaic mutation in an individual at a frequency of 1
in 300 cells could be detected. By scaling up the volume by 10-fold,
4,000 individuals can reasonably be screened in one reaction to
detect a mosaicism frequency of 1 in 300 cells. Only 250 such
Table 3. Summary of p53 mutations detected in plasma of cancer patients with non-metastatic disease
a.
Study
b # patients with tumor mutation # patients with plasma mutation % mutations (plasma/ tumor)
Colorectal cancer
Hibi ’98 10 7
c 70%
c
Mayall ’98 3 2 67%
Wang ’04 31 9
c 29%
c
Bazan ’06 19 7 37%
Total CRC 63 25 40%
Lung cancer
Andriani ’04 26 19 73%
Gonzalez ’00 6 5 83%
Total lung cancer 32 24 75%
Ovarian cancer
Otsuka ’04 12 2 17%
Swisher ’05 60 17
d 28%
d
Total ovarian cancer 72 19 26%
aThe literature was reviewed for English language publications that provided the following information: (1) tumor stage: only non-metastatic tumors, Stages I-III, were
included (for colorectal cancer, modified Dukes Stages A–C); (2) the number of tumor samples with identified p53 mutations; (3) the number of corresponding plasma
DNA samples that were positive for the same personalized p53 mutation detected in the tumor. The literature review included publications cited within Fleischhacker
and Schmidt (2007).
bReferences:
Andriani F et al. (2004).Int J Cancer 108: 91–96.
Bazan V et al. (2006).Ann Oncol 17 Suppl 7: vii84–vii90.
Gonzalez R et al. (2000).Ann Oncol 11: 1097–1104.
Hibi K et al. (1998).Cancer Res 58: 1405–1407.
Mayall F et al.(1998). J Clin Pathol 51: 611–613.
Otsuka J et al. (2004). Int J Gynecol Cancer 14: 459–464.
Swisher EM et al. (2005). Am J Obstet Gynecol 193: 662–667.
Wang Q et al. (2003). Int J Cancer 106: 923–929.
cMutations were detected in serum, rather than plasma.
dMutations were detected in serum or plasma.
doi:10.1371/journal.pone.0007220.t003
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Further scaling up to test 40,000 individuals in a single reaction
could screen 10 million in 250 reactions.
A cocktail of Bi-PAP-A and MAP could be used to screen for
known super hotspots of mutation, i.e. the super hotspots causing
achondroplasia, Apert syndrome, and DMD [32,33,34]. Achon-
droplasia and Apert syndrome, which are dominant, severe,
highly penetrant diseases, are caused by only one or a few
mutations for the overwhelming majority of patients. Individuals
who are mosaic for these mutations may be mildly affected and at
high risk for having offspring with the severe disease. If individuals
with the above germline or somatic mutations were detected at a
frequency of even 1 in 200,000, five such individuals could be
detected per million individuals screened for an incremental cost
of developing and performing the PAP assays of just a few
thousand dollars.
MAP for screening plasma in individuals for early
detection of cancers
Personalized detection of early onset cancer and/or early
cancer recurrence is an area of active investigation. A panel of 21
p53 gene mutation assays (MAP or Bi-PAP-A) may detect the
mutational signature in ,30% of breast cancers, based on an
examination of data from the IARC TP53 database (www-
p53.iarc.fr). Analysis of 10 ml of plasma may be expected to
detect one gram of solid tumors and possibly smaller tumor
burdens. This assay might involve one multiplexed amplification
[35].
For lung and pancreatic cancer, which account for about 35%
of cancer deaths, PAP-based screening may be helpful, as no well
accepted and cost effective screen for early tumors is available.
The screening test would be developed to detect common somatic
mutations found in a large percentage of these cancers. Normally
these tumors are discovered at late stages and associated with
poor prognosis. If the levels of mutation signature found in our
sample of six breast cancers are typical, analysis of 10-fold more
plasma (20 ml of blood) should detect the presence of tumors less
than 1 gram. If the mutation signature increases in subsequent
measurements, a search for the cancer may be cost effective in
high-risk populations. MAP analysis of breast cancer suggests
that roughly one gram of tumor is associated with about one
molecule of tumor mutation signature in the plasma compart-
ment of blood. However, the rate of false positives, which can
result from occasional non-tum o rm o s a i c i s mf o ro n eo ft h e
mutations in the cocktail, would need to be determined in an
epidemiological trial.
The demonstration that EGFR deletions are not detected in
normal lung and blood, coupled with the demonstration that
remnants of presumptive apoptotic, necrotic cancer cells can be
detected in early stage cancer, lead to the possibility that the
common EGFR mutations could be used to detect the presence of
early lung cancer in high-risk populations. A cocktail of MAP
assays for the common 15/18 bp deletions, together with a Bi-
PAP-A assay for the common L858R mutation, could detect about
70–80% of EGFR mutations constituting about 10% of total lung
cancers [10,36]. It remains for future epidemiological studies to
determine if a MAP-based screen is cost effective for detecting
early stage lung cancers when .90% could be surgically cured
[37,38,39]. By identifying the EGFR 15/18 bp deletions in blood,
the ultra high analytical selectivity of MAP could potentially be
applied to early lung cancer detection or possibly facilitate more
rational chemotherapy delivery by monitoring the efficacy of
therapy or predicting recurrence.
Conclusion
The analytical selectivity of MAP (generally one per billion)
and analytical sensitivity of MAP (generally one molecule with a
mutation) is demonstrated. Proof of principle is presented for
three types of clinical applications. MAP was found to be
methodologically robust when utilized i) to detect EGFR
mutations in lung tissue; ii) to detect p53 breast cancer signatures
in plasma and the cellular compartments of blood; or iii) to
screen for mosaicism for common EGFR mutations in a large
population.
Note. While this manuscript was in process, Diehl et al [40]
reported that the cancer mutation signature over the course of
disease in colorectal cancer patients (16 stage IV, 1 stage II, 1 stage
III) can be quantitatively detected. Although the method that was
used (BEAMing) [3] may not be as selective as MAP, the study
confirms the feasibility of personalized monitoring of cancer
therapy and recurrence.
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Found at: doi:10.1371/journal.pone.0007220.s001 (0.03 MB
XLS)
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Figure S1 Schematic of the potential analytical specificities of
PAP-A and Bi-PAP-A A: PAP-A: When a P* oligonucleotide is
annealed to its complementary template, the 39 terminal blocker
can be removed by pyrophosphorolysis in the presence of
pyrophosphate. The activated oligonucleotide can be extended
by DNA polymerization (Left panel, specific amplification). Non-
specific amplification (Non-specific, right panel, type I error) may
occur at a frequency of 10
25, but it is not an efficient template for
subsequent cycles. Significant non-specific amplification (Non-
specific, right panel, type II error) requires mismatch pyropho-
sphorolysis followed by misincorporation by the DNA polymerase,
an event with a frequency estimated to be 3.3610
211. B: Bi-PAP-
A, point mutation: Panel B shows Bi-PAP-A detection of a point
mutation (T.A). The two P* overlap at their 39 termini by one
nucleotide to eliminate polymerase misincorporation (T.A; error
rate: ,10
25) at the mutation position during the opposite primer
extension (the bypass reaction). C: Bi-PAP-A, deletion: When Bi-
PAP-A strategy was applied to detect the EGFR 15 bp deletion, the
downstream and upstream mutant-specific blocked primers are
complementary at three nucleotides at the 39 end of primers and
may form primer dimers (acting as mutant templates) resulting in
false positives due to .10
12 molecules of the primers (2.5 mM)
within the reaction.
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Figure S2 Sequence analyses of false positive products show the
two mechanisms limiting the PAP-A and MAP analytical
specificity. A: False positive is a wild type sequence with one
misincorporation (C.A) during the downstream primer extension;
Sequence analysis shows a segment of size and sequence expected
from wild type DNA with the predicted one misincorporation at
the 39 end of the deleted region (Arrow). B: False positive from two
base mismatch primers is due to slippage of 31 bp upstream; C–D:
8 or 9 bases at the 39 end of P* match with wild-type template with
a loop out of 15 bp segment resulting in a false positive.
Found at: doi:10.1371/journal.pone.0007220.s008 (0.03 MB PPT)
Figure S3 No detection of the EGFR 15 bp deletion in human
lung by MAP in 4 normal lung samples and mushroom control.
The common EGFR 15 bp deletion (sample ID1-4) was not found
in normal lung from 1610
7 copies (0.5610
6 copies/tube 620) of
human lung tissues. The first two lanes in every sample and
mushroom DNA are positive controls spiked with 10 and 4 copies
of mutant templates, respectively. A,T lanes indicate 20 parallel
DNA reactions from the same sample containing 0.5610
6 copies
genomes per tube. The first row shows analytical sensitivity assays
and negative control assays performed simultaneously. The last
row shows mushroom DNA control to monitor the contamination
during DNA extraction.
Found at: doi:10.1371/journal.pone.0007220.s009 (0.26 MB PPT)
Figure S4 No detection of mosaicism in a ‘‘gene pool’’ analysis
of the EGFR 15/18 bp deletions in 6,400 individuals. The
possibility of somatic mosaicism in 6400 control individuals was
tested in leukocyte DNA. Sixteen pools, each containing DNA
from 400 individuals at an aggregated concentration of 200 ng/ml,
were analyzed by MAP for the EGFR 15/18 bp deletions. A series
of analytical sensitivity controls and negative controls are shown
for each deletion mutation. The first two lanes following the DNA
size marker M (WX174 DNA/HaeIII) contain positive controls
spiked with 4 and 2 copies of mutant templates, respectively. Lanes
A–P contain the 16 pooled samples, each with DNA from 400
individuals. Somatic mosaicism for the EGFR 15 bp or 18 bp
deletions was not detected in any sample.
Found at: doi:10.1371/journal.pone.0007220.s010 (0.32 MB PPT)
Figure S5 Real-Time MAP shows a linear relationship in case-5
(also see Table 2). DNA from Patient #5 (see Table 2) with a p53
gene mutation (c.216_217insC) was analyzed by real-time PCR on
the BioRad RQ5 instrument. Real-time MAP shows a linear
relationship between MAP cycle number and the log of the
starting quantity (from 1 to ,10,000 copies) (R
2=0.992).
Found at: doi:10.1371/journal.pone.0007220.s011 (0.12 MB PPT)
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